131 related articles for article (PubMed ID: 23939303)
1. Mouse models of cognitive deficits due to alpha-synuclein pathology.
Magen I; Chesselet MF
J Parkinsons Dis; 2011; 1(3):217-27. PubMed ID: 23939303
[TBL] [Abstract][Full Text] [Related]
2. Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits.
Hatami A; Chesselet MF
Curr Top Behav Neurosci; 2015; 22():303-30. PubMed ID: 25218491
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
4. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.
Rockenstein E; Mallory M; Hashimoto M; Song D; Shults CW; Lang I; Masliah E
J Neurosci Res; 2002 Jun; 68(5):568-78. PubMed ID: 12111846
[TBL] [Abstract][Full Text] [Related]
5. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
6. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
7. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
8. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
Fan Y; Limprasert P; Murray IV; Smith AC; Lee VM; Trojanowski JQ; Sopher BL; La Spada AR
Hum Mol Genet; 2006 Oct; 15(20):3002-11. PubMed ID: 16959793
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
Eschbach J; Danzer KM
Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between alpha-synuclein and Parkinson's disease].
Nishioka K; Hattori N
Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
[TBL] [Abstract][Full Text] [Related]
12. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
13. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
[TBL] [Abstract][Full Text] [Related]
15. How to diagnose dementia with Lewy bodies: state of the art.
Geser F; Wenning GK; Poewe W; McKeith I
Mov Disord; 2005 Aug; 20 Suppl 12():S11-20. PubMed ID: 16092075
[TBL] [Abstract][Full Text] [Related]
16. Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice.
Szegő ÉM; Outeiro TF; Kermer P; Schulz JB
Neurobiol Aging; 2013 Feb; 34(2):589-601. PubMed ID: 22579457
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein in the olfactory system of a mouse model of Parkinson's disease: correlation with olfactory projections.
Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Martinez-Marcos A
Brain Struct Funct; 2012 Apr; 217(2):447-58. PubMed ID: 21928152
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
[TBL] [Abstract][Full Text] [Related]
19. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
20. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
